Mathias Uhlén is co-founder of Atlas Antibodies AB. He is a Professor of Biotechnology at the Royal Institute of Technology in Stockholm and Program Director of the Human Protein Atlas project. Prof. Uhlén is a member of the Board of Directors of Bure AB, Novozymes A/S, Affibody AB, Atlas Therapeutics AB, Antibodypedia AB and SweTree Technologies AB
Biotechnology